NASDAQ · Biotechnology

CTXR (CTXR) Stock

$0.57 -9.81% NASDAQ: CTXR Healthcare

Valuation

MetricValue
Price$0.57
Market Cap$6.37M
P/E Ratio-0.68
P/B Ratio0.20
P/S Ratio1.09
EPS (TTM)$2.82
52-Week High$2.48
52-Week Low$0.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-83.60%
ROA-27.63%
ROCE-50.00%
Gross Margin37.36%
Operating Margin-10.41%
Net Margin-8.23%
Debt/Equity0.01
Current Ratio0.62

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-24.0M$-33.0M$-37.0M$-42.0M$-39.0M
Net Profit$-23.0M$-34.0M$-33.0M$-39.0M$-37.0M
EPS$-5.64$-5.76$-5.57$-5.97$-3.38
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$142.0M$114.0M$104.0M$117.0M$131.0M
Total Liabilities$10.0M$11.0M$12.0M$43.0M$53.0M
Cash$70.0M$42.0M$26.0M$3.0M$4.0M
Borrowings$1.0M$1.0M$0$0$2.0M

Latest News

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies PR Newswire · Jun 1, 2026 Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR Newswire · May 26, 2026 Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? Insider Monkey · May 24, 2026 Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PR Newswire · May 15, 2026 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PR Newswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-28.0M$-29.0M$-28.0M$-27.0M
Investing Cash Flow$-80.0M$0$0$-5.0M$-6.0M
Financing Cash Flow$31.0M$0$0$-4.0M$0
Net Cash Flow$56.0M$-28.0M$-15.0M$-23.0M$1.0M
Free Cash Flow$-64.0M$-28.0M$-29.0M$-28.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-15.51
EV / EBITDA-0.34
FCF Yield-516.54%
Quick Ratio0.16
Interest Coverage—
Return 1Y-67.42%
Return 3Y-98.21%
Return 5Y-98.90%

Ownership

Insiders Held1.80%
Institutions Held3.63%
Institutions Float Held3.70%
Institutional HolderSharesReport Date
Geode Capital Management, LLC246,1582026-03-31
Vanguard Capital Management LLC167,7382026-03-31
Vanguard Fiduciary Trust Co77,7552026-03-31
Blackrock Inc.69,8512026-03-31
HRT Financial LP60,3322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
CRIS $4.69 -4.09% -0.35 $9.14M 0.00%
DARE $1.32 +3.13% -1.94 $12.57M 0.00%

About CTXR

CTXR is led by CEO Leonard L. Mazur, employs 23 people, headquartered in US, publicly traded since 2014.

CTXR stock trades at $0.57 with a market capitalization of $6.37M. The stock is valued at a price-to-earnings (P/E) ratio of -0.68, price-to-book of 0.20, price-to-sales of 1.09. Over the past 52 weeks the stock has ranged between $0.48 and $2.48, and currently trades 77.0% below its 52-week high.

On profitability, CTXR generates a return on equity (ROE) of -83.60%, return on capital employed of -50.00%, an operating margin of -10.41%, a net profit margin of -8.23%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides